Business
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present a quantitative systems
About this update from Travere Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present a quantitative systems pharmacology (QSP) model for predicting the effects of the investigational enzyme replacement therapy pegtibatinase, in classical homocystinuria (HCU), as well as real-world evidence on the prevalence and potential underdiagnosis and/or underreporting of HCU in the United States, at the 2023 Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting in Salt Lake City, UT, March 18-21, 2023. The Company and its collaborators will also provide presentations from the Company’s ongoing longitudinal natural history study of people living with HCU, and HCU incidence estimates based on gnomAD database evaluation at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Salt Lake City, UT, March 14-18, 2023. ACMG Annual Meeting, Salt Palace Convention Center, Salt Lake City, UT – March 14-18, 2023 Insights from the First Genetic Evaluation of a Longitudinal Natural History Study in Classical Homocystinuria (HCU)Platform presentation: #O06Date & Time: March 16, 11 a.m.-12:30 p.m. MT, Room 250 Population-Based Incidence Estimates of Classical Homocystinuria Using the Genome Aggregation Database (gnomAD) Poster #: P561Date & Time: March 16, 10:30 a.m.-12 p.m. MT, Exhibit Hall BCD SIMD Annual Meeting, Hyatt Regency, Salt Lake City, UT – March 18-21, 2023 Development of A Patient Identification Algorithm to Estimate Prevalence of Homocystinuria (HCU) in the United States (US)Poster #: 54Attended poster session: March 19, 7-8 p.m. MT, Exhibit Hall A Quantitative Systems Pharmacology (QSP) Model for Classical Homocystinuria Predicting Efficacy of Treatment Poster #: 79Attended poster session: March 19, 8-9 p.m. MT, Exhibit Hall About Classical Homocystinuria Classical homocystinuria (HCU) is a rare genetic metabolic disorder caused by a deficiency in the enzyme cystathionine beta synthase (CBS). CBS is a pivotal enzyme that is essential for the management of methionine and cysteine in the body. Classical HCU leads to toxic levels of homocysteine that can result in life-threatening thrombotic events such as stroke and heart attacks, ophthalmologic and skeletal complications, as well as developmental delay. Current treatment options are lim...